Obesity Discussion Forums - View Single Post

Obesity Discussion · 10-17-06, 01:50 PM

Epix Sees Positive Data on Obesity Drug

© 2006 The Associated Press

LEXINGTON, Mass. — Drug developer Epix Pharmaceuticals Inc. said Tuesday data from preclinical studies of an obesity and cognitive impairment drug, called PRX-07034, suggest it may help improve cognitive activities in Alzheimer's and schizophrenia patients, and may help obese patients lose weight.

Epix tested PRX-07034 in combination with Aricept, an approved drug for Alzheimer's.

The company said data supports the ongoing Phase 1 clinical program on the drug.

"These preclinical results support our clinical development plan in both obesity and diseases related to cognitive impairment," said Michael Kauffman, chief executive officer, in a prepared statement. "Our Phase 1 trial of PRX-07034 in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of the drug candidate is ongoing, and we anticipate initiating a multiple-dose Phase 1b study with this compound later this year."

Shares of Epix Pharmaceuticals were up 12 cents, or 2.8 percent, at $4.37 in morning trading on the Nasdaq.

Obesity Pill results

10-17-06, 01:50 PM	#1 (permalink)
Obesity Discussion Administrator Join Date: Jan 2005 Location: Phoenix, AZ Posts: 7,955 Weight Statistics 8/1/2006 Start Date: 185 lb Start Weight: 152 lb Current Weight: 155 lb Goal Weight: -33 lb Weight Loss: 5/1/2007 Goal Date:	Epix Sees Positive Data on Obesity Drug Epix Sees Positive Data on Obesity Drug © 2006 The Associated Press LEXINGTON, Mass. — Drug developer Epix Pharmaceuticals Inc. said Tuesday data from preclinical studies of an obesity and cognitive impairment drug, called PRX-07034, suggest it may help improve cognitive activities in Alzheimer's and schizophrenia patients, and may help obese patients lose weight. Epix tested PRX-07034 in combination with Aricept, an approved drug for Alzheimer's. The company said data supports the ongoing Phase 1 clinical program on the drug. "These preclinical results support our clinical development plan in both obesity and diseases related to cognitive impairment," said Michael Kauffman, chief executive officer, in a prepared statement. "Our Phase 1 trial of PRX-07034 in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of the drug candidate is ongoing, and we anticipate initiating a multiple-dose Phase 1b study with this compound later this year." Shares of Epix Pharmaceuticals were up 12 cents, or 2.8 percent, at $4.37 in morning trading on the Nasdaq. Obesity Pill results __________________